What Is Ipamorelin?

Ipamorelin is a pentapeptide growth hormone-releasing peptide (GHRP) first described in a 1998 publication by Raun et al. in the European Journal of Endocrinology . It was developed as part of an effort to find a more selective alternative to existing GHRPs like GHRP-6 and GHRP-2, which, while effective at releasing growth hormone, also affected cortisol, prolactin, and appetite pathways.

Ipamorelin binds to the growth hormone secretagogue receptor (GHS-R1a), the same receptor targeted by the endogenous hunger hormone ghrelin. However, ipamorelin's binding and signaling profile is more selective, which accounts for its cleaner side-effect profile.

Ipamorelin is not FDA-approved for any medical condition. For a general overview, see our Ipamorelin benefits guide.

Key Preclinical Studies

The Foundational Selectivity Study (Raun et al., 1998)

The landmark study that characterized ipamorelin tested it in rats and swine, comparing it to GHRP-6 and growth hormone-releasing hormone (GHRH). Key findings:

• Ipamorelin produced dose-dependent GH release comparable to GHRP-6
• Unlike GHRP-6, ipamorelin did not stimulate ACTH or cortisol release, even at doses up to 200 times higher than the effective GH-releasing dose
• Ipamorelin did not significantly increase prolactin levels
• The GH response was specific and consistent, supporting its classification as the most selective GHRP identified at the time

This study established the foundation for all subsequent ipamorelin research and remains one of the most frequently cited papers in the field.

Bone Health Studies

Multiple animal studies have investigated ipamorelin's effects on bone metabolism:

• A study in ovariectomized rats (a model for postmenopausal bone loss) found that ipamorelin increased bone mineral content and markers of bone formation compared to controls .
• Research published in Bone demonstrated that ipamorelin administration led to increases in both cortical and trabecular bone parameters, mediated through GH and IGF-1 pathways .
• These findings are particularly relevant for age-related bone loss, though human bone density trials are still needed.

Body Composition and Growth Studies

In swine models, ipamorelin demonstrated clear effects on body composition:

• Ipamorelin-treated animals showed increased lean body mass and improved feed efficiency compared to controls .
• Weight gain was driven by lean tissue accretion rather than fat accumulation, consistent with GH-mediated metabolic effects.
• The body composition changes were dose-dependent and reversible after discontinuation.

Gastrointestinal Motility Studies

Animal research has explored ipamorelin's effects on gut function:

• In postoperative ileus models, ipamorelin accelerated the return of normal gastrointestinal motility .
• These findings formed the basis for subsequent human clinical trials examining ipamorelin in post-surgical settings.

Human Clinical Research

Growth Hormone Release Studies

Human pharmacokinetic and pharmacodynamic studies have confirmed several key points:

• Ipamorelin produces dose-dependent GH release in healthy human subjects .
• Peak GH levels occur approximately 30 to 45 minutes after subcutaneous injection.
• The GH pulse pattern closely resembles natural physiological secretion rather than the sustained elevation seen with exogenous GH administration.
• Repeated dosing does not appear to cause significant pituitary tachyphylaxis (loss of response) over standard treatment periods .

Post-Surgical Recovery Trials

The most rigorous human clinical trials for ipamorelin have focused on postoperative recovery:

• A randomized, double-blind, placebo-controlled trial evaluated ipamorelin in patients recovering from abdominal surgery. The study found that ipamorelin accelerated the return of normal bowel function (first bowel movement and tolerance of solid food) compared to placebo .
• The safety profile in these surgical patients was favorable, with no significant differences in adverse events between ipamorelin and placebo groups.
• These trials represent some of the strongest human evidence for any growth hormone secretagogue peptide.

Limitations of Current Human Data

It is important to be transparent about what the human research does and does not show:

• Large-scale, long-term randomized controlled trials for body composition, anti-aging, and performance applications have not been published.
• Most human trials were conducted in specific clinical populations (surgical patients) and may not directly translate to wellness applications.
• Long-term safety data beyond standard study durations is limited.
• Many of the wellness benefits attributed to ipamorelin are extrapolated from its GH-releasing mechanism and from broader GH research rather than from ipamorelin-specific trials.

How Ipamorelin Compares in Research

When evaluated alongside other growth hormone secretagogues in the research literature:

• vs. GHRP-6: Comparable GH release but significantly better selectivity. GHRP-6 raises cortisol, prolactin, and appetite; ipamorelin does not .
• vs. GHRP-2: GHRP-2 is more potent per microgram but less selective. Ipamorelin's advantage is its cleaner profile.
• vs. Hexarelin: Hexarelin is the most potent GHRP but has the greatest cortisol and prolactin elevation and shows tachyphylaxis with continuous use. Ipamorelin avoids both issues.
• vs. MK-677 (Ibutamoren): MK-677 is an oral GH secretagogue with a long half-life. While convenient, it produces 24-hour GH elevation rather than pulsatile release, which some researchers believe is less physiological. MK-677 also significantly increases appetite and can raise fasting glucose .

Dosing and Administration

Based on the available research, standard ipamorelin dosing in wellness settings is:

• Dose: 200 to 300 mcg per injection, 1 to 3 times daily
• Route: Subcutaneous injection
• Timing: On an empty stomach, typically before bed or first thing in the morning
• Cycle length: 8 to 12 weeks followed by a 4 to 6 week rest period

For detailed dosing information, see our Ipamorelin dosage guide. For cycling strategies, visit our Ipamorelin cycling protocol guide.

Benefits and Expected Results

Based on the research reviewed above, ipamorelin may support:

• Selective, dose-dependent growth hormone release
• Improved body composition through GH-mediated metabolic effects
• Enhanced bone mineral content and bone formation
• Accelerated post-surgical and exercise recovery
• Improved sleep quality through enhanced nocturnal GH pulsatility
• Better skin, joint, and connective tissue health via collagen synthesis

The strength of evidence varies by application. GH release and selectivity are well-documented. Body composition and recovery benefits are supported by strong mechanistic data and animal studies but limited direct human evidence for wellness use.

Side Effects and Safety

Across all published research, ipamorelin has demonstrated a favorable safety profile:

• No significant cortisol or prolactin elevation at therapeutic doses
• No meaningful appetite stimulation
• Mild and transient side effects including headache, flushing, and injection site irritation
• No serious adverse events reported in published clinical trials at standard doses

The main limitation is the absence of long-term safety data from large-scale human studies. As with any bioactive compound, physician supervision is essential.

For full safety information, see our Ipamorelin side effects and Ipamorelin safety profile guides.

Who Is a Good Candidate?

Based on the research, ipamorelin may be most appropriate for:

• Adults experiencing age-related GH decline who want a selective, well-tolerated option
• Individuals seeking support for body composition, recovery, or sleep
• Patients who have tried other GHRPs and experienced side effects from cortisol or appetite stimulation
• People willing to commit to a physician-supervised protocol with regular monitoring

It is not recommended for pregnant or nursing women, individuals with active cancer, or those with uncontrolled metabolic conditions.

Frequently Asked Questions

How strong is the research behind ipamorelin?

Ipamorelin has stronger preclinical and early clinical evidence than most peptides in the GH secretagogue class. Its selectivity is well-documented in multiple studies. Human evidence is most robust for post-surgical recovery, while wellness applications are supported primarily by mechanistic data and extrapolation from GH research.

Are there any completed Phase III clinical trials for ipamorelin?

Ipamorelin advanced through Phase II clinical trials for postoperative ileus. To date, it has not completed Phase III trials or received FDA approval for any indication.

How does ipamorelin research compare to HGH research?

Exogenous human growth hormone (HGH) has decades of clinical research and multiple FDA-approved indications. Ipamorelin has a smaller but growing evidence base. The key distinction is that ipamorelin stimulates endogenous GH production rather than replacing it, which carries different risk and benefit profiles.

Is there research on long-term ipamorelin use?

Long-term human studies (beyond standard clinical trial durations of several weeks to months) have not been published. This is a gap in the current evidence base and one reason physicians recommend cycling and regular monitoring.

Where can I read the original ipamorelin studies?

The foundational study by Raun et al. (1998) is published in the European Journal of Endocrinology. Post-surgical clinical trials can be found through PubMed and ClinicalTrials.gov. Your physician can help you interpret the research in the context of your health goals.